Read on Twitter
The #VirtualInvestor KOL Roundtable with Dr. Firas Rahhal, a leading retinal clinician, offered insight on #wetAMD treatment and the potential of ONS-5010/LYTENAVA™ to improve available treatment options. Read the press release: https://bit.ly/32CNa1Y
Lawrence Kenyon, President, CEO and CFO of Outlook Therapeutics, shares the Company’s mission in developing ONS-5010 to treat #wetAMD. Read our press release and watch the video below for more from the KOL Roundtable: https://bit.ly/32CNa1Y $OTLK
Firas Rahhal, MD, a prominent retinal specialist, discusses how frequently he treats patients for #wetAMD and which drugs he uses in his practice. Watch Dr. Rahhal’s video and read the press release: https://bit.ly/32CNa1Y $OTLK
Top retinal surgeon Firas Rahhal, MD, describes how anti-VEGF drugs revolutionized the treatment of retinal diseases. See his video below and read the full release: https://bit.ly/32CNa1Y $OTLK
Learn how anti-VEGF drugs treat #wetAMD, as described by Dr. Firas Rahhal, a noted retinal specialist. Watch the video and read the full press release from our Virtual KOL Roundtable: https://bit.ly/32CNa1Y $OTLK
Hear exactly how retinal physicians administer anti-VEGF drugs into the eye to treat retinal diseases such as #wetAMD, according to Dr. Firas Rahhal. Watch the video below, or read the press release here: https://bit.ly/32CNa1Y $OTLK
Where do retinal physicians get the off-label bevacizumab they use to treat patients for #wetAMD and other retinal diseases? Listen to noted retinal specialist Firas Rahhal, MD, explain in the video how compounding pharmacies are involved. Read here: https://bit.ly/32CNa1Y $OTLK
Terry Dagnon, COO of Outlook Therapeutics, explains why the Company is developing the first ophthalmic formulation of bevacizumab for retinal disease. Watch the video and read the release: https://bit.ly/32CNa1Y $OTLK
